AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01448-06v1
51/5/1869    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oyakhirome, S.
Right arrow Articles by Kremsner, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oyakhirome, S.
Right arrow Articles by Kremsner, P. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2007, p. 1869-1871, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01448-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria{triangledown} ,{dagger}

Sunny Oyakhirome,1 Saadou Issifou,1 Peter Pongratz,1 Fortune Barondi,1 Michael Ramharter,1,3 Jürgen F. Kun,2 Michel A. Missinou,1,2 Bertrand Lell,1,2 and Peter G. Kremsner1,2*

Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon,1 Institute of Tropical Medicine, Department of Parasitology, University of Tübingen, Tübingen, Germany,2 Department of Internal Medicine I, Division of Infectious Diseases, Medical University of Vienna, Vienna, Austria3

Received 18 November 2006/ Returned for modification 6 January 2007/ Accepted 12 February 2007

Fosmidomycin-clindamycin therapy given every 12 h for 3 days was compared with a standard single oral dose of sulfadoxine-pyrimethamine. The two treatments showed comparably good tolerabilities and had an identical high degree of efficacy of 94% in a randomized trial carried out with 105 Gabonese children aged 3 to 14 years with uncomplicated malaria. These antimalarials merit further clinical exploration.

* Corresponding author. Mailing address: Institute for Tropical Medicine, Department for Parasitology, University of Tübingen, Wilhelmstrasse 27, 72074 Tübingen, Germany. Phone: 49-7071-2987179. Fax: 49-7071-295189. E-mail: peter.kremsner{at}uni-tuebingen.de

{triangledown} Published ahead of print on 26 February 2007.

{dagger} The registration number for this trial is NCT00214643.

Antimicrobial Agents and Chemotherapy, May 2007, p. 1869-1871, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01448-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.